A Phase 1 Open-Label, Dose-Escalation Study of Veliparib in Combination With Bimonthly FOLFIRI in Subjects With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 12 Mar 2018
At a glance
- Drugs Veliparib (Primary) ; Fluorouracil; Folinic acid; Irinotecan
- Indications Colorectal cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Abbott Laboratories; AbbVie
- 12 Mar 2018 Results published in the British Journal of Cancer.
- 19 May 2014 Planned End Date changed from 1 Dec 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov.
- 31 Jul 2013 Planned end date changed from 1 Oct 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History